Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.52 |
| ▸ | ITGAV | P06756 | 15/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 8/20 | 0.43 |
| ▸ | ITGB8 | P26012 | 8/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20156008 | 0.85 | ITGAV (0.53) | ITGB3ITGAVITGB5ITGA2BCXCR4 | |
| SCHEMBL20156094 | 0.82 | ITGAV (0.49) | ITGB3ITGAVITGB5ITGA2BCXCR4 | |
| SCHEMBL20156009 | 0.80 | CXCR4 (0.47) | ITGB3ITGAVITGB5CXCR4ITGB6 | |
| SCHEMBL23912918 | 0.79 | ITGB3 (0.56) | ITGB3ITGAVITGB5ITGA2BCXCR4 | |
| SCHEMBL23912903 | 0.77 | ITGB3 (0.54) | ITGB3ITGAVITGB5ITGA2BCXCR4 | |
| SCHEMBL20156054 | 0.77 | ITGAV (0.47) | ITGB3ITGAVITGA2BCXCR4ITGB6 | |
| SCHEMBL20156055 | 0.77 | ITGAV (0.47) | ITGB3ITGAVITGA2BCXCR4ITGB6 | |
| SCHEMBL22223451 | 0.77 | ITGB3 (0.68) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL20156097 | 0.76 | ITGAV (0.48) | ITGB3ITGAVITGB5ITGA2BCXCR4 | |
| SCHEMBL20156359 | 0.76 | ITGAV (0.49) | ITGB3ITGAVITGB5ITGA2BCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089358-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |